Elevance Health (NYSE:ELV – Get Free Report) was upgraded by research analysts at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm presently has a $510.00 price target on the stock. Argus‘s target price would indicate a potential upside of 17.38% from the company’s current price.
Several other analysts also recently issued reports on ELV. TD Cowen upped their price objective on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Mizuho set a $490.00 target price on shares of Elevance Health in a report on Friday, October 23rd. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a report on Wednesday, November 11th. Finally, Royal Bank Of Canada upped their price target on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a report on Thursday, October 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $458.91.
Read Our Latest Research Report on Elevance Health
Elevance Health Stock Down 2.6%
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. During the same quarter last year, the company posted $6.03 earnings per share. The company’s revenue for the quarter was up .7% compared to the same quarter last year. Research analysts forecast that Elevance Health will post 29.15 EPS for the current year.
Insider Transactions at Elevance Health
In related news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares in the company, valued at $6,533,560. This represents a 8.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is currently owned by corporate insiders.
Institutional Trading of Elevance Health
Hedge funds have recently modified their holdings of the company. Field & Main Bank increased its position in Elevance Health by 1.3% during the second quarter. Field & Main Bank now owns 1,883 shares of the company’s stock worth $728,000 after buying an additional 25 shares during the period. Simplicity Wealth LLC lifted its stake in Elevance Health by 1.3% in the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company’s stock valued at $754,000 after buying an additional 25 shares during the last quarter. Tranquilli Financial Advisor LLC boosted its holdings in shares of Elevance Health by 1.3% in the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock valued at $805,000 after acquiring an additional 26 shares during the period. Mather Group LLC. boosted its holdings in shares of Elevance Health by 3.5% in the third quarter. Mather Group LLC. now owns 766 shares of the company’s stock valued at $298,000 after acquiring an additional 26 shares during the period. Finally, 55 North Private Wealth LLC grew its position in shares of Elevance Health by 4.5% during the third quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after acquiring an additional 26 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Further Reading
- Five stocks we like better than Elevance Health
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
